Xenetic Biosciences Reports Q1 2025 Results: Revenue Up 16.1% to $0.6M; Net Loss at $0.9M

Reuters
14 May
Xenetic Biosciences Reports Q1 2025 Results: Revenue Up 16.1% to $0.6M; Net Loss at $0.9M

Xenetic Biosciences, Inc. (NASDAQ: XBIO), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies for difficult-to-treat cancers, has released its financial results for the first quarter ended March 31, 2025. The company reported a net loss of approximately $0.9 million for the quarter. Revenue increased by approximately $0.1 million, or 16.1%, reaching approximately $0.6 million compared to approximately $0.5 million in the same period in 2024. Operating costs and expenses decreased by approximately $244,000, or 13.7%, to about $1.5 million from approximately $1.8 million in the comparable quarter in 2024. This decrease was primarily attributed to reduced personnel costs and share-based expenses following the departure of the company's former Chief Executive Officer and Chief Scientific Officer in the second quarter of 2024. Xenetic concluded the quarter with approximately $5.2 million in cash to support its operations. The company continues to focus on exploratory investigator-initiated clinical studies in collaboration with institutional partners. Significant progress has been made in the development of the DNase I program, with efforts moving towards an Investigational New Drug $(IND.AU)$ application and a first-in-human study for the treatment of pancreatic carcinoma. Additionally, Xenetic's collaboration with PeriNess Ltd. has led to a Clinical Study Agreement to advance the DNase platform for treating relapsed/refractory osteosarcoma and Ewing sarcoma. The company remains committed to pursuing strategic collaborations to advance its technology and development programs efficiently.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1027259) on May 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10